B-Cell Lymphomas Coverage from Every Angle

Michael Dickinson, MBBS, on Clinical Implications of New Findings on Glofitamab for DLBCL

Posted: Monday, June 27, 2022

Michael Dickinson, MBBS, of the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and The University of Melbourne, discusses what could be a promising therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the bispecific monoclonal antibody glofitamab. Given that these patients have been heavily pretreated, including with CAR T cells, Dr. Dickinson offers clinical pearls on administering glofitamab and managing side effects, including neurotoxicities.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.